Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 87

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 87
---
 other expenses3,479 4,158 6,692 8,173 Total external development program expenses12,137 16,849 28,569 31,559 Internal employee-related expenses9,978 9,334 20,473 19,554 Total research and development expenses22,115 26,183 49,042 51,113 Other segment items(a)10,461 18,406 39,478 34,171 Net earnings$22,499 $19,916 $10,672 $20,040 (a) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration gain or loss, net interest and other income, interest expense, and income tax expense, whose amounts are disclosed in the condensed consolidated statement of earnings.

19

14.    Composition of Other Balance Sheet Items

The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):

Inventories, Net June 30,2025December 31,2024(unaudited)Raw materials$8,419 $11,127 Work in process15,650 26,725 Finished goods19,954 16,441 Total$44,023 $54,293 

Property and Equipment, Net June 30,2025December 31,2024(unaudited)Lab equipment and furniture$13,959 $13,370 Leasehold improvements14,023 14,023 Software883 883 Computer equipment1,183 1,112 Subtotal30,048 29,388 Less accumulated depreciation and amortization(18,979)(17,843)Property and equipment, net$11,069 $11,545 Depreciation and amortization expense on property and equipment was approximately $0.5 million and $1.1 million for the three and six months ended June 30, 2025 and $0.6 million and $1.2 million for the three and six months ended June 30, 2024, respectively.

Accounts Payable and Accrued LiabilitiesJune 30,2025December 31,2024(unaudited)Accounts payable$8,215 $4,587 Accrued compensation, benefits, & related accruals20,463 21,225 Accrued sales & marketing15,960 11,007